IMS Health catches layoff bug

Call it the ripple effect. Making a living off pharmaceutical companies suddenly isn't so lucrative: IMS Health, the market research company responsible for so much of the hard data on drug sales, is laying off about 10 percent of its work force.

The company sells detailed market data and medical data to drug makers. That info is mostly used by sales departments--which of course have been shrinking like the Arctic ice lately. Guess it goes to show that layoffs can be contagious.

- here's the article from The Wall Street Journal

Suggested Articles

Compared with the FDA "boxed warning," the EMA version puts a smaller restriction on the higher dose but broadens the cautionary language.

Shionogi's newest antibiotic Fetroja has now earned the FDA's approval, but will a mortality-rate warning scuttle the drug's chances?

Novartis' Sandoz doubled down in Japan as Lupin retreated. Dr. Reddy's posted a loss tied to its Zantac recall. Aslan's varlitinib failed again.